DIVISLAB - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 4.0
| Stock Code | DIVISLAB | Market Cap | 1,72,621 Cr. | Current Price | 6,502 ₹ | High / Low | 7,078 ₹ |
| Stock P/E | 67.1 | Book Value | 578 ₹ | Dividend Yield | 0.46 % | ROCE | 20.6 % |
| ROE | 15.6 % | Face Value | 2.00 ₹ | DMA 50 | 6,220 ₹ | DMA 200 | 6,216 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.05 % | PAT Qtr | 653 Cr. | PAT Prev Qtr | 696 Cr. |
| RSI | 66.1 | MACD | 103 | Volume | 3,93,137 | Avg Vol 1Wk | 3,35,462 |
| Low price | 5,636 ₹ | High price | 7,078 ₹ | PEG Ratio | -7.29 | Debt to equity | 0.01 |
| 52w Index | 60.1 % | Qtr Profit Var | 9.88 % | EPS | 94.8 ₹ | Industry PE | 30.1 |
Analysis: Divi’s Laboratories (DIVISLAB) shows strong fundamentals with ROCE (20.6%) and ROE (15.6%), supported by a debt-free balance sheet (0.01). Current price (6,502 ₹) is above both DMA 50 (6,220 ₹) and DMA 200 (6,216 ₹), confirming bullish momentum. RSI at 66.1 suggests mildly overbought conditions, while MACD (103) supports positive momentum. Quarterly PAT declined slightly (653 Cr. vs 696 Cr.), though overall profit variation remains positive (9.88%). Valuation is stretched with P/E of 67.1 compared to industry PE of 30.1, and PEG ratio (-7.29) highlights growth concerns despite strong EPS (94.8 ₹). Technicals show strong support around DMA levels.
Optimal Entry Price: Around 6,250–6,300 ₹ (near DMA support).
Exit Strategy if Holding: Consider booking profits near 6,800–6,900 ₹ unless momentum sustains above 7,000 ₹ resistance.
✅ Positive
- Strong ROCE (20.6%) and ROE (15.6%).
- Debt-free balance sheet ensures financial stability.
- Quarterly PAT remains strong despite slight decline.
- FII holdings increased (+0.21%), showing foreign investor confidence.
⚠️ Limitation
- High P/E (67.1) compared to industry average (30.1).
- PEG ratio (-7.29) suggests poor growth prospects.
- Quarterly PAT declined (653 Cr. vs 696 Cr.).
- DII holdings decreased (-0.05%), showing reduced domestic interest.
📰 Company Negative News
- No major negative news reported, but stretched valuation and slight profit decline are concerns.
🌟 Company Positive News
- Strong efficiency metrics (ROCE and ROE).
- Debt-free status enhances financial flexibility.
- Foreign institutional investors increased their stake.
🏭 Industry
- Industry P/E at 30.1 suggests Divi’s trades at a steep premium.
- Pharmaceutical sector remains resilient with global demand for APIs and formulations.
📌 Conclusion
Divi’s Laboratories is a good candidate for swing trading. Entry around 6,250–6,300 ₹ offers a favorable risk-reward setup, while exit near 6,800–6,900 ₹ is advisable unless momentum sustains above 7,000 ₹. Strong fundamentals and debt-free status are positives, but premium valuation and slight profit decline warrant cautious optimism.
Would you like me to expand this with a technical chart outlook, peer comparison, or sector growth analysis?